JP2022518527A5 - - Google Patents

Info

Publication number
JP2022518527A5
JP2022518527A5 JP2021543164A JP2021543164A JP2022518527A5 JP 2022518527 A5 JP2022518527 A5 JP 2022518527A5 JP 2021543164 A JP2021543164 A JP 2021543164A JP 2021543164 A JP2021543164 A JP 2021543164A JP 2022518527 A5 JP2022518527 A5 JP 2022518527A5
Authority
JP
Japan
Prior art keywords
apomorphine
patient
dose
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015434 external-priority patent/WO2020160005A1/en
Publication of JP2022518527A publication Critical patent/JP2022518527A/ja
Publication of JP2022518527A5 publication Critical patent/JP2022518527A5/ja
Pending legal-status Critical Current

Links

JP2021543164A 2019-01-28 2020-01-28 パーキンソン病の患者を治療する方法 Pending JP2022518527A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797660P 2019-01-28 2019-01-28
US62/797,660 2019-01-28
US201962861077P 2019-06-13 2019-06-13
US201962861067P 2019-06-13 2019-06-13
US62/861,077 2019-06-13
US62/861,067 2019-06-13
PCT/US2020/015434 WO2020160005A1 (en) 2019-01-28 2020-01-28 Methods of treating a patient having parkinson's disease

Publications (2)

Publication Number Publication Date
JP2022518527A JP2022518527A (ja) 2022-03-15
JP2022518527A5 true JP2022518527A5 (https=) 2023-02-01

Family

ID=71841403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543164A Pending JP2022518527A (ja) 2019-01-28 2020-01-28 パーキンソン病の患者を治療する方法

Country Status (6)

Country Link
US (1) US20210315882A1 (https=)
EP (1) EP3917502A4 (https=)
JP (1) JP2022518527A (https=)
CA (1) CA3121531A1 (https=)
MX (1) MX2021008986A (https=)
WO (1) WO2020160005A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578461A3 (en) * 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
WO2023172649A1 (en) * 2022-03-11 2023-09-14 Alexza Pharmaceuticals, Inc. Apomorphine hydrochloride trimethanolate, its polymorphs and its uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2967349B1 (fr) * 2010-11-15 2013-06-14 Oreal Composition solide cosmetique de maquillage et/ou de soin
EP4578461A3 (en) * 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa

Similar Documents

Publication Publication Date Title
JP2023088944A5 (https=)
JP2022544711A5 (https=)
JP2022191257A5 (https=)
JP2017061561A (ja) ニタゾキサニドの制御放出医薬配合物
JP2018520189A5 (https=)
JP2024174962A5 (https=)
JP2006513184A5 (https=)
JP2020502261A5 (https=)
JP2021526138A5 (https=)
CN105228622A (zh) 用于治疗多发性硬化的PPARγ激动剂
JP2022523530A5 (https=)
JP6824924B2 (ja) 運動障害をベフィラドールで処置するための方法
JP2022518527A5 (https=)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022536088A5 (https=)
JPWO2020250915A5 (https=)
JP2005508983A (ja) Ｐｄｅ４又はｐｄｅ３／４阻害剤及び抗リウマチ薬の複合薬
JP2021516241A5 (https=)
JP2021532176A5 (https=)
JP2017508737A5 (https=)
JP2025511096A5 (https=)
JP2022514561A5 (https=)
JP2011506607A5 (https=)
JP2872809B2 (ja) モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物
JP2021522241A5 (https=)